Varigheden (median) af sidste behandling med proteasehæmmere var 149 uger for patienter, som fik fosamprenavir og ritonavir 2 gange daglig (49% havde tidligere fået ≥ 2 PI’ er), og 130 uger for patienter, som fik lopi - navir/ ritonavir (40% havde tidligere fået ≥ 2 PI’ er).
The median durations of prior exposure to protease inhibitors were 149 weeks for patients receiving fosamprenavir with ritonavir twice daily (49% received ≥ 2 prior PIs) and 130 weeks for patients receiving lopinavir/ ritonavir (40% received ≥ 2 prior PIs).